在CRISPR屏幕中,ATPase VCP被确定为胆管癌中可用药物的治疗漏洞
Wu Yang1,2, Siying Wang1,2, Shuyi Ji3,4
1State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, China.
概括
这项研究确定了含有瓦洛的蛋白质 (VCP) 作为胆管癌 (CCA) 的点. 将VCP抑制剂与老化剂相结合,为抑制CCA生长提供了一个有前途的双重疗法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 胆管癌 (CCA) 是一种具有很少治疗选择的侵袭性癌症.
- 含有瓦洛辛的蛋白质 (VCP) 被确定为CCA的关键依赖.
- 治疗耐药性是CCA治疗的一个挑战,部分原因是持续老化的细胞.
研究的目的:
- 研究VCP作为CCA中的治疗点.
- 为了评估VCP抑制剂CB-5339的疗效,单独或与老化剂结合使用.
- 探索CCA的新型治疗策略.
主要方法:
- 全基因组的CRISPR-Cas9查以确定CCA依赖性.
- 使用VCP抑制剂CB-5339对患者衍生的CCA器官进行复合查.
- 在体外和体内使用CB-5339和老化剂 (ABT-263,conatumumab) 的联合治疗.
- 在CCA患者样本中对VCP表达的临床分析.
主要成果:
- 在CCA中,VCP被确定为关键依赖.
- 通过诱导细胞衰老,CB-5339抑制了CCA的增殖.
- 与CB-5339和老化剂的联合治疗表明增强了瘤抑制.
- 在CCA患者中,VCP过度表达与预后不佳相关.
结论:
- 针对VCP来诱导衰老,然后是衰老清除,为CCA提供了一个"一两拳"的治疗策略.
- 这种方法有望改善胆管癌的治疗结果.
- VCP抑制和老化疗法为CCA治疗提供了一个新的途径.
相关概念视频
01:59CRISPR
57.5K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
57.5K
01:28CRISPR/Cas9 Genome Editing
1.7K
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
1.7K